Abbott Laboratories Maintains FY21 Outlook - Quick Facts

While reporting financial results for the second quarter on Thursday, Abbott Laboratories (ABT) maintained its earnings and adjusted earnings guidance for the full-year 2021, which was slashed in early June due to significantly lower recent and projected COVID-19 diagnostic testing demand.

For fiscal 2021, the company continues to project earnings from continuing operations in a range of $2.75 to $2.95 per share and adjusted earnings from continuing operations in a range of $4.30 to $4.50 per share, reflecting strong double-digit growth from last year.

On average, 21 analysts polled by Thomson Reuters expect the company to report earnings of $4.36 per share for the year. Analysts' estimates typically exclude special items.

On June 11, 2021, the board of directors of Abbott declared the company's quarterly cash dividend of $0.45 per share, payable on August 16, 2021 to shareholders of record at the close of business on July 15, 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
CVS Health is set to recruit qualified candidates to fill 25,000 clinical and retail jobs during a one-day national career event on Friday, September 24. This will enable CVS to meet the high demand for pharmacists, pharmacy technicians, nurses, and retail store associates to support flu season, COVID-19 vaccinations and testing. Twitter, Inc. (TWTR) announced Monday that it has entered into a binding agreement to settle the consolidated class action lawsuit commenced in 2016 in the United States District Court for the Northern District of California. Under the terms of the proposed settlement, Twitter will pay $809.5 million... Drug major Pfizer has again expanded the earlier two recalls of its anti-smoking Drug Chantix (Varenicline) in the form of tablets, to now include all the lots, for the potential presence of nitrosamine impurity, N-Nitroso- varenicline, at or above the FDA interim acceptable intake limit (ADI), the U.S. Food and Drug Administration or FDA said in a statement.
Follow RTT